Lite includes recombinant human interferon alpha-2b, produced by a strain of the bacteria Escherichia coli, in which genetically engineered introduced gene of interferon alfa-2b human.
Interferon alfa-2b has antiviral, immunomodulatory, antiproliferative and antibacterial properties . The antiviral effect is mediated by activation of several intracellular enzymes that inhibit viral replication. Immunomodulatory effects manifested, first of all, increasing cell-mediated immune reactions, which increases the efficiency of the immune response against viruses, intracellular parasites and cells which have undergone a neoplastic transformation. This is achieved by activation of CD8 + killer T cells, NK-cells (natural killer cells), enhancing differentiation of B lymphocytes and the production of antibodies to, activation of the monocyte-macrophage system and definition of equipoise phagocytosis as well as increasing the expression of molecules of the major histocompatibility complex I type, which increases the likelihood detection of infected cells by cells of the immune system. Activation under the influence of leukocyte interferon contained in all mucosal layers ensures their active participation in the elimination of lesions; In addition, due to the effect of interferon is achieved by restoring the production of secretory immunoglobulin A. The antibacterial effect is mediated by the immune system, strengthens under the influence of interferon.
Taurine helps to normalize metabolic processes and tissue regeneration, has a membrane and immunomodulatory effects. As a powerful antioxidant, taurine interacts directly with the reactive oxygen species, the excessive accumulation of which contributes to the development of pathological processes. Taurine helps to preserve the biological activity of interferon, enhancing the therapeutic effect of the drug.
At intranasal application due to the high concentration of the source of infection is achieved by a pronounced local antiviral and immunostimulatory effects.
Systemic absorption of the drug slightly – low bioavailability of drugs when administered intranasally is associated with the operation of a particular protein family of 25 proteins that make up the nasal mucosa and controlling transport of molecular and cellular objects penetrating the mucous membranes. At the same time, a certain definition of equipoise amount of the drug reaches the systemic circulation, thereby achieving systemic immunomodulatory effect.
Prevention and treatment of influenza and acute respiratory viral infections in adults and children older than 14 years.
Dosing and Administration
The drug is used intranasally by aerosol administration of one dose (1 dose = 1 short press on the dispenser). At the first sign of the disease Genferon ® Light is administered intranasally for 5 days by a single dose (one press of the dispenser) in each nostril 3 times a day (single dose of approximately 50 000 IU of interferon alfa daily should not exceed 500 000 IU). Upon contact with SARS patients and / or drug is administered supercooling according to the scheme 2 times a day for 5-7 days. Prevention courses are repeated, if necessary.
Instructions for use Spray:
- Remove the protective cap.
- Before using for the first time, click on the dispenser several times until a thin stream.
- When you use keep the bottle upright.
- Make a single injection of the drug into the dispenser by pressing each nostril in turn.
- After use, close the dispenser screw cap.
To prevent the spread of infection is recommended individual use.
Side effects when using definition of equipoise the drug Genferon ® Light is not observed.
Hypersensitivity to interferon alfa-2b or any other components of the preparation.
Children under 14 years old.
should be used with caution in patients with epistaxis.
Use during pregnancy and lactation
is allowed to use during the whole period of pregnancy.